Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1811 + SHR-1701 + capecitabine
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
SHR-A1811 + SHR-1701 + capecitabine is an investigational combination therapy consisting of three agents: - **SHR-A1811**: a third-generation antibody-drug conjugate (ADC) targeting HER2, showing promising antitumor activity and acceptable tolerability in HER2-positive cancers. - **SHR-1701**: also known as retlirafusp alfa, a bifunctional fusion protein that targets both programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β) pathways, acting simultaneously as an immune checkpoint inhibitor and TGF-β trap. SHR-1701 is under investigation for various advanced solid tumors, including gastric cancer, esophageal cancer, colorectal cancer, and others. - **Capecitabine**: an oral prodrug of 5-fluorouracil (5-FU), a well-established antimetabolite chemotherapeutic agent commonly used in gastrointestinal and breast cancers. Clinical research is examining the safety and efficacy of this combination in HER2-expressing advanced solid tumors, notably gastric and gastroesophageal junction cancers, among others, with ongoing or planned trials. Each component targets different but complementary mechanisms of tumor growth and immune evasion.
- Other names
- retlirafusp alfa + SHR-A1811 + capecitabine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on SHR-A1811 + SHR-1701 + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1811 + SHR-1701 + capecitabine.